KALA BIO, Inc. filed a Form 8-K on November 16, 2026, disclosing that a Nasdaq Hearings Panel granted the company a conditional extension to maintain its listing on The Nasdaq Capital Market following a minimum bid price deficiency notification received on August 27, 2026.
Key Highlights
- Deficiency notice: KALA BIO received a Staff Determination Letter from Nasdaq on August 27, 2026, citing that its common stock closing bid price had been below $1.00 per share for 30 consecutive business days, from July 16, 2026 through August 26, 2026.
- Listing rule at issue: The company was found not in compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
- Panel hearing: The company met with the Nasdaq Hearings Panel on October 6, 2026, and on November 13, 2026 the Panel granted a conditional extension to remain listed.
- Key condition - bid price: The company must evidence a closing bid price of at least $1.00 per share for ten consecutive business days by November 30, 2026, and maintain that level through February 23, 2027.
- Additional condition: If the company becomes non-compliant with any other Nasdaq listing rule before February 23, 2027, it will have seven days to advise the Panel on a cure plan, after which the Panel will decide whether to grant an exception or delist the company.
- Post-compliance monitor: If the company maintains compliance until February 23, 2027, the Panel stated it intends to impose a discretionary monitor for the following year.
- No assurance provided: According to the filing, "there can be no assurance that the Company will be able meet the Panel's conditions or maintain compliance with the requirements for continued listing on The Nasdaq Capital Market."
KALA BIO's Conditional Nasdaq Listing Extension: Terms and Timeline
According to the Form 8-K filed with the SEC on November 16, 2026, KALA BIO, Inc. (NASDAQ:KALA) disclosed that its common stock was flagged for a minimum bid price deficiency after the closing bid price remained below $1.00 per share for 30 consecutive business days. The Staff Determination Letter, received August 27, 2026, identified the deficiency period as July 16, 2026 through August 26, 2026, constituting non-compliance with Nasdaq Listing Rule 5550(a)(2).
The company disclosed that it met with the Nasdaq Hearings Panel on October 6, 2026. On November 13, 2026, the Panel issued its decision granting the company's request to continue its listing, subject to specific conditions. Those conditions require the company to demonstrate a closing bid price of at least $1.00 per share for ten consecutive business days no later than November 30, 2026, and to sustain that level on each trading day through February 23, 2027. The filing also noted that the Panel reserved the right to reconsider its decision "based on any event, condition or circumstance that exists or develops that would, in the opinion of the Panel, make continued listing of the Common Stock on Nasdaq inadvisable or unwarranted."
The filing further disclosed that if the company remains compliant through February 23, 2027, the Panel intends to impose a discretionary monitor for one year after that date. The company characterized statements about its ability to meet the Panel's conditions as forward-looking statements subject to risks and uncertainties, including those detailed in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other regulatory filings. The filing was signed by Avi Minkowitz, Chief Executive Officer.
What Was Disclosed
KALA BIO disclosed receipt of a Nasdaq minimum bid price deficiency notice, its subsequent hearing before the Nasdaq Hearings Panel, and the Panel's November 13, 2026 decision granting a conditional listing extension with a compliance deadline of February 23, 2027.




Please wait processing your request...